| Literature DB >> 33947411 |
Ines Buchholz1, You-Shan Feng1,2, Maresa Buchholz1, Lewis E Kazis3, Thomas Kohlmann4.
Abstract
BACKGROUND: The translated and culturally adapted German version of the Veterans Rand 36 Items Health Survey (VR-36), and its short form, the VR-12 counterpart, were validated in a German sample of orthopedic (n = 399) and psychosomatic (n = 292) inpatient rehabilitation patients.Entities:
Keywords: Health assessment; Health-related quality of life; Quality of life; SF-12; SF-36; Veterans Rand 36 Items Health Survey
Mesh:
Year: 2021 PMID: 33947411 PMCID: PMC8097879 DOI: 10.1186/s12955-021-01722-y
Source DB: PubMed Journal: Health Qual Life Outcomes ISSN: 1477-7525 Impact factor: 3.186
Fig. 1Flow chart of the translation process
Fig. 2Survey study design
Sample characterization at baseline (t1)
| VR-12 | SF-12 | VR-36 | SF-36 | Total | |
|---|---|---|---|---|---|
| Total | 177/151 | 171/156 | 169/158 | 174/161 | 691/626 |
| Orthopedics | 103/96 | 99/91 | 97/95 | 100/96 | 399/378 |
| Psychosomatics | 74/55 | 72/65 | 72/63 | 74/65 | 292/248 |
| Age, M ± SD (range) | 52.0 ± 11.3 (23–89) | 53.2 ± 11.3 (22–84) | 54.1 ± 8.9 (23–78) | 52.0 ± 10.7 (20–77) | 52.8 ± 10.6 (20–89) |
| Sex, % women | 68.0 | 69.6 | 68.1 | 65.1 | 67.7 |
| Single | 13.4 | 13.9 | 8.6 | 17.3 | 13.3 |
| Married/living with partner | 65.1 | 67.5 | 65.6 | 63.7 | 65.5 |
| High school | 28.8 | 25.2 | 24.3 | 28.7 | 26.8 |
| Secondary school (10 years) | 56.5 | 55.6 | 53.8 | 53.4 | 54.8 |
| Fully employed | 45.8 | 48.0 | 49.1 | 50.6 | 48.3 |
| Pension application, % yes | 10.2 | 11.3 | 8.5 | 14.9 | 11.3 |
| Duration of rehabilitation, mean days | 26.8 | 28.2 | 27.4 | 27.7 | 27.5 |
| Sick leave, days in the last year, M ± SD | 130 ± 162 | 121 ± 162 | 118 ± 152 | 109 ± 2138 | 119 ± 153 |
M mean, SD standard deviation, SF-12 Short Form 12 Items Health Survey, SF-36 Short Form 36 Items Health Survey. All group comparisons were not significant (p > 0.05)
Percent complete items in each scale by instrument and patient subgroup
| Instrument (n) | PF | RP | BP | GH | VT | SF | RE | MH | |
|---|---|---|---|---|---|---|---|---|---|
| VR-36 (n = 169) | 94.7 | 93.5 | 97 | 93.5 | 96.4 | 98.2 | 95.3 | 95.9 | |
| SF-36 (n = 174) | 95.4 | 97.7 | 96.6 | 93.1 | 96.6 | 97.7 | 98.9 | 96.6 | |
| Orthopedic | VR-36 (n = 97) | 93.8 | 91.8 | 96.9 | 92.8 | 95.9 | 97.9 | 93.8 | 92.8 |
| SF-36 (n = 100) | 94 | 98 | 97 | 90 | 95 | 97 | 99 | 95 | |
| Psychosomatic | VR-36 (n = 72) | 95.8 | 95.8 | 97.2 | 94.4 | 97.2 | 98.6 | 97.2 | 100 |
| SF-36 (n = 74) | 97.3 | 97.3 | 95.9 | 93.2 | 98.6 | 98.6 | 98.6 | 98.6 | |
| Female | VR-36 (n = 111) | 91.9 | 94.6 | 96.4 | 94.6 | 96.4 | 98.2 | 94.6 | 96.4 |
| SF-36 (n = 112) | 94.6 | 97.3 | 95.5 | 87.5 | 95.5 | 97.3 | 98.2 | 95.5 | |
| Male | VR-36 (n = 52) | 100 | 90.4 | 98.1 | 92.3 | 96.2 | 98.1 | 96.2 | 94.2 |
| SF-36 (n = 60) | 96.7 | 97.3 | 98.2 | 98.3 | 98.3 | 98.3 | 100 | 98.3 | |
| ≤ 45 years | VR-36 (n = 26) | 96.2 | 96.2 | 100 | 92.3 | 100 | 100 | 96.2 | 100 |
| SF-36 (n = 41) | 97.6 | 95.1 | 95.1 | 92.7 | 97.6 | 97.6 | 97.6 | 97.6 | |
| 46–64 years | VR-36 (n = 114) | 94.4 | 92.7 | 96.8 | 95.2 | 96 | 97.6 | 96 | 95.2 |
| SF-36 (n = 115) | 96.5 | 99.1 | 97.4 | 93.4 | 97.4 | 98.3 | 99.1 | 97.4 | |
| ≥ 65 years | VR-36 (n = 19) | 94.7 | 94.7 | 94.7 | 84.2 | 94.7 | 100 | 89.5 | 94.7 |
| SF-36 (n = 18) | 88.9 | 94.4 | 94.4 | 88.9 | 88.9 | 94.4 | 100 | 88.9 | |
| ≤ 10 years | VR-36 (n = 115) | 93 | 91.3 | 95.7 | 92.2 | 95.7 | 98.3 | 93 | 93.9 |
| SF-36 (n = 117) | 94.9 | 98.3 | 95.7 | 91.5 | 95.7 | 97.4 | 99.1 | 95.7 | |
| > 10 years | VR-36 (n = 46) | 97.8 | 97.8 | 100 | 95.7 | 97.8 | 97.8 | 100 | 100 |
| SF-36 (n = 55) | 96.4 | 96.4 | 98.2 | 94.5 | 98.2 | 98.2 | 98.2 | 98.2 | |
PF Physical functioning, RP Role physical, BP Bodily pain, GH General health, VT Vitality, SF Social functioning, RE Role emotion, MH Mental health, n sample size
Distribution properties of PCS and MCS by instrument and version
| Instrument | n | M ± SD | Min–Max | Kurtosis | Excess | K–S-Test |
|---|---|---|---|---|---|---|
| PCSVR-36 | 155 | 38.50 ± 10.15 | 11.7–67.8 | 0.151 | − 0.226 | |
| MCSVR-36 | 155 | 36.18 ± 14.21 | 12.9–66.6 | 0.437 | − 0.817 | 0.049 |
| PCSVR-12 | 173 | 36.30 ± 11.55 | 12.7–59.3 | 0.141 | − 0.969 | |
| MCSVR-12 | 173 | 37.23 ± 13.82 | 8.4–70.2 | 0.389 | − 0.527 | 0.001 |
| PCSSF-12 | 150 | 36.95 ± 10.95 | 15.5–61.6 | 0.27 | − 0.724 | |
| MCSSF-12 | 150 | 39.04 ± 12.33 | 17.6–65.4 | 0.268 | − 1.001 | 0.002 |
| PCSSF-36 | 168 | 37.50 ± 11.67 | 13.8–66.1 | 0.289 | − 0.465 | |
| MCSSF-36 | 168 | 39.03 ± 15.62 | 2.04–73.2 | 0.055 | − 0.989 | 0.005 |
K-S-Test Kolmogorov-Smirnov-Test, M mean, SD standard deviation, n sample size
Fig. 3a Kernel density estimation for PCS and MCS b Kernel plots of the scales of the VR-36 and SF-36
Construct validity: comparison of Pearson correlation coefficients (rp) across SF-12/VR-12 and SF-36/VR-36
| Physical component score (PCS) | PCSSF-12 | PCSVR-12 | ∆SF-12-VR-12 | p-value | PCSSF-36 | PCSVR-36 | ∆SF-36-VR-36 | p-value |
|---|---|---|---|---|---|---|---|---|
| EQ VAS | 0.480 | 0.327 | 0.153 | 0.052 | 0.348 | 0.328 | 0.020 | 0.420 |
| IMET | − 0.499 | − 0.514 | 0.015 | 0.429 | − 0.362 | − 0.457 | 0.095 | 0.155 |
| GCPS Pain | − 0.514 | − 0.620 | 0.106 | 0.082 | − 0.420 | − 0.412 | − 0.008 | 0.466 |
| HFAQ | 0.670 | 0.759 | − 0.089 | 0.052 | 0.746 | 0.660 | 0.086 | 0.064 |
| CDC Physical healthy days | − 0.604 | − 0.669 | 0.065 | 0.165 | − 0.569 | − 0.554 | − 0.015 | 0.423 |
| GCPS Pain Intensity | − 0.547 | − 0.624 | 0.077 | 0.149 | − 0.664 | − 0.632 | − 0.032 | 0.312 |
| GCPS Pain Disability | − 0.581 | − 0.615 | 0.034 | 0.319 | − 0.661 | − 0.586 | − 0.075 | 0.137 |
| DASS Anxiety | − 0.156 | 0.003 | − 0.159 | 0.085 | 0.143 | − 0.094 | 0.237 | 0.017 |
| DASS Depression | 0.023 | 0.124 | − 0.101 | 0.183 | 0.164 | − 0.005 | 0.169 | 0.065 |
| DASS Stress | 0.063 | 0.109 | − 0.046 | 0.340 | 0.297 | 0.104 | 0.193 | 0.036 |
| IRES-VT | 0.106 | − 0.082 | 0.188 | 0.415 | − 0.151 | − 0.015 | − 0.136 | 0.111 |
| CDC Mentally healthy days | 0.174 | 0.119 | 0.055 | 0.309 | 0.234 | 0.118 | 0.116 | 0.493 |
CDC healthy days, EQ-5D-5L EuroQol-5 Dimensions, HFAQ Hannover Functional Ability Questionnaire, IMET Index of the Assessment of Health Impairments, IRES-VT Subscale Vitality of the Indicators of Rehabilitation Status, GCPS Graded Chronic Pain Scale, SF-12 Short-Form 12 Items Health Survey, SF-36 Short Form 36 Items Health Survey, VR-12 Veterans Rand 12 Items Health Survey, VR-36 Veterans Rand 36 Items Health Survey; p-value for the comparison of two correlation coefficients from independent samples [63]
Known groups validity for the PCSVR-36 and the MCSVR-36
| Subgroups | PCSVR-36 | MCSVR-36 | ||
|---|---|---|---|---|
| mean ± SD | p-value | mean ± SD | p-value | |
| < 0.001 | < 0.001 | |||
| Orthopedic patients (n = 87) | 34.2 ± 9.0 | 41.9 ± 13.9 | ||
| Psychosomatic patients (n = 68) | 44.1 ± 8.8 | 28.9 ± 11.0 | ||
| < 0.001 | 0.149 | |||
| Medical follow-up-treatment (n = 30) | 29.6 ± 8.9 | 44.1 ± 13.9 | ||
| Curative treatment (n = 54) | 36.7 ± 8.1 | 39.6 ± 13.3 | ||
| 0.181 | 0.133 | |||
| < 45 years (n = 25) | 41.3 ± 8.4 | 31.8 ± 13.6 | ||
| 45–65 years (n = 114) | 38.3 ± 10.7 | 37.5 ± 14.4 | ||
| > 65 years (n = 16) | 35.5 ± 8.0 | 33.5 ± 12.9 | ||
| < 0.001 | < 0.001 | |||
| ≤ 27 days (n = 71) | 35.2 ± 9.2 | 40.7 ± 13.5 | ||
| > 27 days (n = 66) | 42.4 ± 10.3 | 32.5 ± 13.1 | ||
| 0.081 | 0.281 | |||
| ≤ 100 days (n = 76) | 40.3 ± 10.6 | 38.1 ± 14.1 | ||
| > 100 days (n = 66) | 37.3 ± 9.7 | 35.6 ± 14.0 | ||
| < 0.01 | < 0.001 | |||
| Excellent/very good/good (n = 60) | 42.7 ± 11.0 | 43.4 ± 13.3 | ||
| Fair/poor (n = 92) | 35.7 ± 8.7 | 31.8 ± 13.0 | ||
aOrthopedic patients only
bDays of sick leave in the last 12 month
cSRH Self-rated health. Patients reporting “excellent”, “very good” or “good” health and those reporting “poor” or “fair” health were aggregated. SD standard deviation
Known groups validity for the PCSVR-12 and MCSVR-12
| Subgroups | PCSVR-12 | MCSVR-12 | ||
|---|---|---|---|---|
| mean ± SD | p-value | mean ± SD | p-value | |
| < 0.001 | < 0.001 | |||
| Orthopedic patients (n = 100) | 31.20 ± 9.49 | 42.21 ± 13.73 | ||
| Psychosomatic patients (n = 73) | 43.13 ± 10.55 | 30.41 ± 10.74 | ||
| 0.023 | 0.187 | |||
| Medical follow-up treatment (n = 37) | 28.37 ± 9.67 | 44.56 ± 15.34 | ||
| Curative therapy (n = 67) | 32.88 ± 9.20 | 40.58 ± 12.42 | ||
| 0.079 | 0.004 | |||
| < 45 years (n = 42) | 37.15 ± 11.77 | 35.84 ± 14.14 | ||
| 45–65 years (n = 111) | 36.86 ± 11.37 | 36.02 ± 12.94 | ||
| > 65 years (n = 20) | 30.78 ± 11.13 | 46.87 ± 14.77 | ||
| < 0.001 | < 0.001 | |||
| ≤ 27 days (n = 85) | 31.69 ± 10.74 | 42.45 ± 13.64 | ||
| > 27 days (n = 71) | 41.77 ± 9.91 | 31.89 ± 11.64 | ||
| 0.021 | 0.667 | |||
| ≤ 100 days (n = 82) | 38.56 ± 10.71 | 37.58 ± 13.66 | ||
| > 100 days (n = 82) | 34.41 ± 12.04 | 36.65 ± 13.96 | ||
| < 0.001 | < 0.001 | |||
| Excellent/very good/good (n = 67) | 41.56 ± 11.49 | 43.42 ± 13.81 | ||
| Fair/poor (n = 104) | 32.38 ± 10.19 | 33.50 ± 12.37 |
aOrthopedic patients only
bDays of sick leave in the last 12 month
cSRH Self-rated health. Patients reporting “excellent”, “very good” or “good” health and those reporting “fair” or “poor” health were aggregated. SD standard deviation
Cronbachs α in each scale by instrument
| Instrument (nb) | Scale (number of items) | |||||||
|---|---|---|---|---|---|---|---|---|
| PF (10) | RP (4) | BP (2) | GHa (5) | VT (4) | SF (2) | RE (3) | MH (5) | |
| VR-36 (n = 164) | 0.92 | 0.93 | 0.89 | 0.79 | 0.85 | 0.87 | 0.94 | 0.87 |
| SF-36 (n = 172) | 0.92 | 0.85 | 0.88 | 0.70 | 0.82 | 0.80 | 0.89 | 0.90 |
aWithout GH item 1 αVR-36 = 0.75, αSF-36 = 0.66
bDue to missing values, n varies between n = 158 and n = 164 (of n = 169) for the VR-36 and n = 159 to n = 172 (of n = 174) for the SF-36
Standardized response means (SRM) and standardized effect sizes (SES) by instrument and clinical indication
| Version | Orthopedics | Psychosomatics | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SES | SRM | rt1/t2 | SES | SRM | rt1/t2 | |||||||
| ni/s (nc) | PCS | MCS | PCS | MCS | PCS/MCS | ni/s (nc) | PCS | MCS | PCS | MCS | PCS/MCS | |
| VR-36 | 78 (82) | 0.235 | 0.298 | 0.328 | 0.452 | 0.74/0.77 | 56 (61) | 0.102 | 0.522 | 0.127 | 0.527 | 0.65/0.62 |
| SF-36 | 83 (88) | 0.317 | 0.165 | 0.460 | 0.241 | 0.77/0.74 | 59 (60) | 0.250 | 0.818 | 0.331 | 0.820 | 0.72/0.54 |
| VR-12 | 88 (93) | 0.381 | 0.357 | 0.545 | 0.586 | 0.73/0.81 | 50 (57) | 0.218 | 1.027 | 0.317 | 0.876 | 0.73/0.35 |
| SF-12 | 63 (69) | 0.398 | 0.482 | 0.695 | 0.586 | 0.84/0.65 | 50 (54) | 0.277 | 0.840 | 0.357 | 1.060 | 0.69/0.69 |
SES standardized effect size, SRM standardized response mean, r Pearson correlation coefficient, n number of patients reporting improved or stable health defined by GHP1 (SRH, item 1 of the SF-36), n n complete: number of all cases (improved, deteriorated, unchanged), PCS physical summary score, MCS mental summary score